125I粒子可更换持续照射系统治疗不可切除肝门部胆管癌  

Clinical evaluation of iodine-125 brachytherapy in hilar cholangiocarcinoma

作　　者：邹雷[1] 金焰[1] 乔鸥[1] 朱秀芳[1] 莫一我[1] 

机构地区：[1]云南省第一人民医院肝胆外科,650032

出　　处：《中华肝胆外科杂志》2015年第6期418-420,共3页Chinese Journal of Hepatobiliary Surgery

摘　　要：肝门部胆管癌是常见的胆道恶性肿瘤.国内外文献报道晚期患者根治性切除率20％左右,半数患者就诊时已失去手术机会,而不能切除者平均生存期约6个月.因此,寻找一种能提高生存率的姑息性治疗方法显得尤为重要.2013年6月至2014年6月,云南省第一人民医院应用“胆管内外125I粒子可更换持续照射系统”这一新型治疗方法,治疗不可切除肝门部胆管癌患者7例.所有患者至今仍存活,平均生存时间5.2个月,中位生存时间为7.8个月,最长生存期12个月.该法效果确切、并发症少,可显著延长患者生存期,应用前景广阔.Hilar cholangiocarcinoma is a common bile duct cancer.The radical resection rate of end-stage malignancies reported in literature is about 20％.Half of the patients have lost the chance of operation at the time of care,while the average survival time in the patients who can not be operated is about six months.Therefore,for most patients,looking for a palliative treatment which can prolong the survival time is particularly important.From June 2013 to June 2014,our hospital applied iodine-125 brachytherapy,to treat 7 patients with unresectable hilar cholangio carcinoma.All the patients are still alive,the average survival time of 7 patients is 5.2 months up to now,with median survival time being 7.8 months,and longest survival time being 12 months.With good outcomes,few complications,as well as significantly prolonged survival time,iodine125 brachytherapy is regarded with broad clinical applications.

关 键 词：肝门部胆管癌 新治疗方法 碘125粒子 内照射 

分 类 号：R735.8[医药卫生—肿瘤]